Latest News !
 

Monash Research Leads To ASC Warning On Assay Hit Pains 

Dr Boreham's Crucible: GI Dynamics

Budget 2017: 1st MRFF Funds, Steady As She Goes
- Biotech Daily Editorial Comment

Biotech Daily Editorial: Welcome To 2017 

2016 - The Year In Review: Money, Malcolm & Medical Marijuana

10-Year BDI-40 Up 163%, ASX200 Up 3%, Big Caps Up 308%

Novartis Buys Spinifex For $916m

BRIL Group Senate Innovation Submission:
Set Aside 25% Of $20bn MRFF For Commercialization

 

 

March BDI-40 Up 10%, ASX200 Up 3%
Big Caps Up 5%, NBI Down 1%

Mesoblast Up 46%, Prana 40%; Viralytics 32%; IDT Down 17%, Ellex 14%

April 3, 2017

March was a very good month for the Biotech Daily Top 40 Index (BDI-40), which climbed 10.0 percent, compared to the ASX200 up 2.7 percent.

 

Sirtex strengthened its hold as the largest biotech by market capitalization at $1,033 million, closely followed by the resurgent Mesoblast at $976 million – having briefly broken the billion dollar barrier last week – and Nanosonics at $923 million.

 

The Nasdaq Biotechnology Index (NBI) fell 1.25 percent in March, while the collective three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) climbed 4.7 percent in March and 23.2 percent for the year to March 31, led by the Magic Pudding of CSL, up 6.2 percent in March, with Cochlear up 3.6 percent and Resmed retreating 0.7 percent (see charts below).

 

For the 12 months to March 31, 2017, the BDI-40 was up 7.1 percent, the ASX200 was up 15.4 percent and the NBI was up 12.5 percent.

 

And March was definitely medical marijuana month, with Zelda up 200 percent to $30 million, followed by Creso up 175 percent to $33 million on a Brazilian distributor, MMJ up 161.8 percent to $144 million, Botanix up 54.5 percent to $17 million and Medlab Clinical up 11.1 percent to $90 million, with several claiming import and trial approvals.

 

The BDI-40 saw 23 companies climbing, 11 by more than 10 percent and 16 falling, with just four by more than 10 percent, while ITL held steady at $45 million.

 

Mesoblast improved on clinical announcements, but surprised by climbing higher on a discounted capital raise, up $309 million or 46.3 percent to close the month at $976 million, followed by Prana reporting good clinical news for the first time in five months, up 40.1 percent to $38 million, Viralytics (31.5%), Living Cell (29.8%), Pro Medicus (26.9%), Compumedics (23.1%), Cellmid, (17.6%) and Genetic Signatures (15.8%).

 

IDT led the few notable March falls, down 16.6 percent to $35 million, followed by Ellex (13.6%), Atcor (13.3%) and Avita (11.4%).

 

Outside the BDI-40, GI Dynamics, Immuron, Imugene, LBT, Medibio, Optiscan and Paradigm were all recovering or showing new promise.

 

 

BDI-40 v S&P ASX200 Jun 30, 2006 to Mar 31, 2017 

 

 

BDI-40 v S&P ASX200 Mar 31, 2016 to Mar 31, 2017 

 

Big Caps (Cochlear, CSL, Resmed) Mar 31, 2016 to Mar 31, 2017